We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Indivior Pharmaceuticals Inc. (INDV) Down 5.3% Since Last Earnings Report: Can It Rebound?
Read MoreHide Full Article
It has been about a month since the last earnings report for Indivior Pharmaceuticals Inc. (INDV - Free Report) . Shares have lost about 5.3% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Indivior Pharmaceuticals Inc. due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Indivior Beats Q2 Earnings Estimates, 2026 Outlook Raised
Indivior delivered adjusted earnings of $1.15 per share in the second quarter of 2026, up 125.5% year over year and beating the Zacks Consensus Estimate of 97 cents.
Total revenues rose 13.6% year over year to $343 million, primarily due to strong U.S. Sublocade performance. The metric beat the Zacks Consensus Estimate of $308 million.
Total Sublocade net revenues increased 21% year over year to a quarterly record of $253 million.
U.S. Sublocade revenues increased 22% to $238 million, driven by strong dispense unit volume growth, favorable price/mix and gross-to-net adjustments.
Dispense unit volume increased 18% year over year, supported by strong market demand and commercial execution.
The quarter saw record new patient starts for the company, with roughly 32,816 patients beginning Sublocade treatment. As of June 30, 2026, more than 545,000 U.S. patients had been prescribed Sublocade since launch.
U.S. sublingual and other product revenues increased to $57 million compared with $52 million in the prior-year quarter. Rest of World revenues declined 6.5% year over year to $43 million.
In the second quarter of 2026, overall U.S. revenues rose to $300 million, up from $256 million a year ago.
Indivior's Cost Base Lifts Profitability
Indivior continued to improve profitability through disciplined cost management. Adjusted operating expenses declined 33% year over year to $112 million.
Adjusted EBITDA surged 111% year over year to $186 million.
Balance Sheet & Share Repurchases
The company ended the quarter with $249 million in cash and investments, up from $201 million as of March 31, 2026. During the quarter, the company repurchased about 4.7 million shares for $175 million at an average price of $37.52.
The company expects net revenues to be in the range of $1.295-$1.365 billion, up from its previous guidance of $1.215-$1.285 billion.
Indivior also lifted its total Sublocade net revenues forecast to $1.01-$1.05 billion from $950-$990 million, implying approximately 20% year-over-year growth at the midpoint.
The increase in guidance reflects stronger-than-expected dispense-unit growth and improved commercial dispense yields, supported by favorable product mix trends.
Adjusted EBITDA is projected at $700-$740 million, up from the prior range of $620-$660 million. The adjusted operating expense outlook was maintained at $430-$450 million.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a upward trend in estimates review.
VGM Scores
Currently, Indivior Pharmaceuticals Inc. has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with a D. However, the stock was allocated a score of B on the value side, putting it in the second quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of this revision looks promising. It comes with little surprise Indivior Pharmaceuticals Inc. has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.
Performance of an Industry Player
Indivior Pharmaceuticals Inc. is part of the Zacks Medical - Drugs industry. Over the past month, Ionis Pharmaceuticals (IONS - Free Report) , a stock from the same industry, has gained 8.7%. The company reported its results for the quarter ended June 2026 more than a month ago.
Ionis Pharmaceuticals reported revenues of $268 million in the last reported quarter, representing a year-over-year change of -40.7%. EPS of -$0.43 for the same period compares with $0.86 a year ago.
For the current quarter, Ionis Pharmaceuticals is expected to post a loss of $0.89 per share, indicating a change of -45.9% from the year-ago quarter. The Zacks Consensus Estimate has changed -1.1% over the last 30 days.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Ionis Pharmaceuticals. Also, the stock has a VGM Score of F.
View the Zacks #1 Rank List
Image: Bigstock
Indivior Pharmaceuticals Inc. (INDV) Down 5.3% Since Last Earnings Report: Can It Rebound?
It has been about a month since the last earnings report for Indivior Pharmaceuticals Inc. (INDV - Free Report) . Shares have lost about 5.3% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Indivior Pharmaceuticals Inc. due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Indivior Beats Q2 Earnings Estimates, 2026 Outlook Raised
Indivior delivered adjusted earnings of $1.15 per share in the second quarter of 2026, up 125.5% year over year and beating the Zacks Consensus Estimate of 97 cents.
Total revenues rose 13.6% year over year to $343 million, primarily due to strong U.S. Sublocade performance. The metric beat the Zacks Consensus Estimate of $308 million.
Total Sublocade net revenues increased 21% year over year to a quarterly record of $253 million.
U.S. Sublocade revenues increased 22% to $238 million, driven by strong dispense unit volume growth, favorable price/mix and gross-to-net adjustments.
Dispense unit volume increased 18% year over year, supported by strong market demand and commercial execution.
The quarter saw record new patient starts for the company, with roughly 32,816 patients beginning Sublocade treatment. As of June 30, 2026, more than 545,000 U.S. patients had been prescribed Sublocade since launch.
U.S. sublingual and other product revenues increased to $57 million compared with $52 million in the prior-year quarter. Rest of World revenues declined 6.5% year over year to $43 million.
In the second quarter of 2026, overall U.S. revenues rose to $300 million, up from $256 million a year ago.
Indivior's Cost Base Lifts Profitability
Indivior continued to improve profitability through disciplined cost management. Adjusted operating expenses declined 33% year over year to $112 million.
Adjusted EBITDA surged 111% year over year to $186 million.
Balance Sheet & Share Repurchases
The company ended the quarter with $249 million in cash and investments, up from $201 million as of March 31, 2026. During the quarter, the company repurchased about 4.7 million shares for $175 million at an average price of $37.52.
Indivior Raises 2026 Outlook
Reflecting stronger-than-expected commercial performance, Indivior increased its full-year 2026 financial guidance.
The company expects net revenues to be in the range of $1.295-$1.365 billion, up from its previous guidance of $1.215-$1.285 billion.
Indivior also lifted its total Sublocade net revenues forecast to $1.01-$1.05 billion from $950-$990 million, implying approximately 20% year-over-year growth at the midpoint.
The increase in guidance reflects stronger-than-expected dispense-unit growth and improved commercial dispense yields, supported by favorable product mix trends.
Adjusted EBITDA is projected at $700-$740 million, up from the prior range of $620-$660 million. The adjusted operating expense outlook was maintained at $430-$450 million.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a upward trend in estimates review.
VGM Scores
Currently, Indivior Pharmaceuticals Inc. has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with a D. However, the stock was allocated a score of B on the value side, putting it in the second quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of this revision looks promising. It comes with little surprise Indivior Pharmaceuticals Inc. has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.
Performance of an Industry Player
Indivior Pharmaceuticals Inc. is part of the Zacks Medical - Drugs industry. Over the past month, Ionis Pharmaceuticals (IONS - Free Report) , a stock from the same industry, has gained 8.7%. The company reported its results for the quarter ended June 2026 more than a month ago.
Ionis Pharmaceuticals reported revenues of $268 million in the last reported quarter, representing a year-over-year change of -40.7%. EPS of -$0.43 for the same period compares with $0.86 a year ago.
For the current quarter, Ionis Pharmaceuticals is expected to post a loss of $0.89 per share, indicating a change of -45.9% from the year-ago quarter. The Zacks Consensus Estimate has changed -1.1% over the last 30 days.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Ionis Pharmaceuticals. Also, the stock has a VGM Score of F.